The unexpected success of NRTIs in second-line treatment

Lancet Infect Dis. 2018 Jan;18(1):3-5. doi: 10.1016/S1473-3099(17)30631-X. Epub 2017 Nov 3.

Authors

Andrew M Hill¹, Francois Venter²

Affiliations

¹ Department of Translational Medicine, University of Liverpool, Liverpool, L69 3GF, UK. Electronic address: microhaart@aol.com.
² Wits Reproductive Health and HIV Institute, University of Witswatersrand, Johannesburg, South Africa.

PMID: 29108798
DOI: 10.1016/S1473-3099(17)30631-X

No abstract available

Publication types

Comment

MeSH terms

Anti-HIV Agents*
DNA-Directed RNA Polymerases
Follow-Up Studies
HIV / drug effects
Lopinavir
Raltegravir Potassium
Reverse Transcriptase Inhibitors*

Substances

Anti-HIV Agents
Reverse Transcriptase Inhibitors
Lopinavir
Raltegravir Potassium
DNA-Directed RNA Polymerases